2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests

Figures & data

Figure 1. Representative results of pre-transfusion compatibility test using IATs in a Chinese patient undergoing DARA treatment. (A) Antibody screening results of patients before and after 2-ME/DTT treatment. (B) Cross-matching results of patients before and after 2-ME/DTT treatment. (C) Antigen detection results before and after 2-ME treatment in panel RBCs. -E, anti-E antibody; -K, anti-K antibody; S1 to S3, antibody screening cells 1–3; P, major cross-matching of this patient; -D, anti-D antibody; -C, anti-C antibody; -c, anti-c antibody; -e, anti-e antibody; -M, anti-M antibody; -N, anti-N antibody; -S, anti-S antibody; -s, anti-s antibody; -Jk^a, anti-Jk^a antibody; -Jk^b, anti-Jk^b antibody; -Fy^a, anti-Fy^a antibody; -Fy^b, anti-Fy^b antibody; -Di^a, anti-Di^a antibody.

Figure 2. Representative results of pre-transfusion compatibility test using Polybrene method in a Chinese patient treated with DARA. The results were all negative, while IgG anti-E plasma showed a 2+ agglutination intensity. (A) Different agglutination intensity of E+ RBCs reacted with human IgG Anti-E diluted from 1:16 to 1:256 in IATs. (B) Antibody screening results (left three tubes: anti-E control, right three tubes: Patient S1 to S3 means 3 antibody screening cells). (C) Major cross-matching results (left: anti-E control, right: Patient).